COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Laia GarrigósCristina SauraClara Martinez-VilaAlberto ZambelliMark BowerBarbara PistilliMatteo LambertiniDiego OttavianiNikolaos DiamantisAilsa LumsdenSonia PernasDaniele GeneraliElia SeguíGemma ViñasEudald FelipAna SanchezGianpiero RizzoArmando SantoroAlessio CortelliniYlenia PeroneJohn ChesterMaria IglesiasMarta BettiBruno VincenziMichela LibertiniFrancesca MazzoniFederica ZorattoRossana BerardiAnnalisa GuidaRachel WuerstleinAngela LoizidouRachel SharkeyJuan AguilarMarta MatasChiara SaggiaLorenzo ChiudinelliEmeline Colomba-BlamebleMyria GalaziUma MukherjeeMieke Van HemelrijckMar MarinCarla StrinaAleix PratHelena PlaEva Maria CiruelosAlexia BertuzziLucia Del MastroGiampiero PorzioThomas Newsom-DavisIsabel RuizMaria Belen DelanyMarco KrengliVittoria FotiaAlessandro ViansoneNeha ChopraMargarita RomeoRamon SalazarIgnacio PerezFrancesca d'AvanzoMichela FranchiManuela MilaniFanny PommeretMarco TucciPaolo PedrazzoliNadia HarbeckDaniela FerranteDavid J PinatoAlessandra GennariPublished in: Therapeutic advances in medical oncology (2021)
In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.